11月17日，上海商汤善萃医疗科技有限公司（简称"商汤医疗"）宣布于近日完成数亿元新一轮战略融 资。本轮投资方包括联想创投、联创资本、九弦资本、申冉投资等多家投资机构。 今年年初，商汤医疗已获美的系盈峰控股、人民卫生出版社集团旗下人卫科技发展公司等机构的上亿元 投资。 据介绍，目前商汤医疗已同步启动A轮融资，认购金额超5亿元，投后估值超30亿元。（智通财经记者 秦盛） 商汤医疗成立于2022年。商汤医疗与新加坡IHH医疗(集团)旗下百汇放射科的合作，是2025世界人工智 能大会（WAIC）发布的《中国智·惠世界（2025）》案例集唯一入选的医疗案例。 ...

编辑 杨娟娟 新京报贝壳财经讯 11月17日，据商汤医疗官方公众号消息，近日商汤医疗完成数亿元新一轮战略融 资，本轮投资方包括联想创投、联创资本、九弦资本、申冉投资等多家知名投资机构。目前，商汤医疗 已同步启动A轮融资，认购金额超5亿元，投后估值超30亿元。 ...

上述协议签署后，杭州更好与葛航形成一致行动人关系。2025年11月14日，杭州更好与锦福源（海 南）私募基金管理合伙企业（有限合伙）（作为锦福源长弓五号私募证券投资基金管理人）（以下简 称"锦福源"）签署了《关于创业慧康科技股份有限公司的表决权委托暨一致行动协议》，约定锦福源将 其持有的公司40,000,000股股份（约占公司总股本的2.58%）对应的全部表决权委托给杭州更好行使。 上述协议签署后，杭州更好与锦福源形成一致行动人关系。上述葛航、锦福源分别将其持有的全部公司 股份对应的表决权委托给杭州更好行使，合称"表决权委托"。 根据上述协议和杭州更好出具的说明，表决权委托完成后，杭州更好将拥有公司12.64%股份对应 的全部表决权，成为公司第一大股东，杭州更好将与公司商议择机启动向特定对象发行事项（"向特定 对象发行股票"）。本次协议转让股份过户后，杭州更好拟向公司提名四名非独立董事、两名独立董事 人选（"董事会改选"）。无论公司是否完成向特定对象发行股票事项，若杭州更好提名的上述董事全部 当选且占公司董事会席位的半数以上，将导致公司控制权变更，杭州更好成为公司的控股股东。为确保 本次权益变动过渡期间公司业 ...

Core Insights - SenseTime Medical has completed a new round of strategic financing amounting to several hundred million yuan, with participation from notable investors including Lenovo Capital, Lianchuang Capital, Jiuxian Capital, and Shenran Investment [1] - The company has also initiated its Series A financing round, with subscription amounts exceeding 500 million yuan and a post-investment valuation exceeding 3 billion yuan [1] Group 1 - The recent financing round attracted multiple well-known investment institutions [1] - The total amount raised in the new financing round is in the hundreds of millions of yuan [1] - The post-investment valuation of SenseTime Medical has surpassed 3 billion yuan [1] Group 2 - The Series A financing round has already begun, indicating ongoing investor interest [1] - Subscription amounts for the Series A round have exceeded 500 million yuan [1]

Core Insights - SenseTime Medical has completed a new round of strategic financing amounting to several hundred million yuan, with notable investors including Lenovo Capital, Lianchuang Capital, Jiuxian Capital, and Shenran Investment [1] - The company has simultaneously initiated its Series A financing round, with subscription amounts exceeding 500 million yuan and a post-investment valuation exceeding 3 billion yuan [1] Investment Details - The recent financing round attracted multiple well-known investment institutions, indicating strong market interest and confidence in SenseTime Medical's potential [1] - The ongoing Series A financing aims to raise additional capital, further enhancing the company's financial position and growth prospects [1] Valuation Metrics - Post-investment valuation of SenseTime Medical is reported to be over 3 billion yuan, reflecting a significant increase in its market valuation [1] - The subscription amount for the Series A round has already surpassed 500 million yuan, showcasing robust investor demand [1]

于完成收购事项及投票权委托后，本公司将持有目标公司股权(表决权)约12.64%。于目标公司董事会组 成调整后，目标公司董事会将由十一名董事组成，超过半数的董事会成员由买方提名。因此，紧随完成 收购事项、投票权委托及根据股份转让协议所规定的目标公司董事会组成调整后，本公司将于目标公司 董事会中拥有大多数董事席位，并将能够对通过目标公司董事会决议案施加重大影响。目标公司被视为 本公司的附属公司，目标公司的财务业绩将于本集团的综合财务报表综合入账。 本次收购创业慧康控制权，是华检医疗在国家战略指引下，基于对AI医疗产业趋势的深刻洞察，依托 自身独特的"K×A"智能资本模式，对一家拥有深厚积淀与创新活力的行业领军企业进行的战略性投资。 通过此次并购及后续的全面赋能与深度融合，华检医疗将与创业慧康携手，共同开啓中国"AI+医疗"的 新篇章，不仅为双方股东创造持续且丰厚的回报，亦将为推动中国医疗健康事业的进步、服务国家发展 大局贡献坚实力量。 华检医疗(01931)发布公告，于2025年11月12日，本公司(买方)与卖方订立股份转让协议及第一份投票权 委托协议，本公司已有条件同意收购，而卖方已有条件同意出售目标公司创业慧 ...

Core Insights - Health Catalyst, Inc. (NASDAQ:HCAT) is actively participating in several investor conferences to showcase its data and analytics solutions and discuss its strategies and performance [1][6] Conference Participation - The company will attend the Stephens Annual Investment Conference in Nashville on November 19, 2025, featuring a fireside chat [2] - Health Catalyst will also be present at the Canaccord Genuity MedTech, Diagnostics and Digital Health and Services Forum in New York on November 20, 2025, offering one-on-one meetings [2] - Additional participation includes the 8th Annual Evercore Healthcare Conference in Miami on December 2, 2025, and Citi's 2025 Global Healthcare Conference in Miami on December 3, 2025 [2] Technology and Operations - Health Catalyst's operations are centered around its cloud-based technology, Health Catalyst Ignite, which utilizes AI-enabled data and analytics to enhance clinical, financial, and operational outcomes [3][6] - The platform supports over 1,100 organizations globally, delivering billions in measurable results by transforming complex data into actionable insights [3][6] Financial Performance - In its recent financial report, Health Catalyst achieved earnings per share of $0.06, surpassing the estimated $0.05 [4][6] - The company reported a revenue of $76.32 million, exceeding the estimated $73.97 million [4][6] - Health Catalyst demonstrated efficiency with an asset turnover ratio of 0.51 [4][6] - For the most recent quarter, the company reported a cost of revenue of $38.51 million and operating expenses of $55.33 million, resulting in a gross profit of $37.82 million [5]

智通财经APP讯，华检医疗(01931)发布公告，于2025年11月12日，本公司(买方)与卖方订立股份转让协 议及第一份投票权委托协议，本公司已有条件同意收购，而卖方已有条件同意出售目标公司创业慧康 (300451.SZ)9652.51万股A股，相当于目标公司于本公告日期已发行股本总额的6.23%。收购事项的目标 股份价格为每股目标股份人民币5.18元。收购事项的代价为人民币5亿元。同时，卖方已同意自2025年 11月12日开始，委托其于目标公司所持部分股份(合共1.558亿股A股)所附带的投票权，相当于目标公司 于本公告日期已发行股本总额的10.06%。此外，买方与私募基金已订立第二份投票权委托协议，并同 意自2025年11月14日开始，委托其于目标公司所持部分股份(合共4000万股A股)所附带的投票权，相当 于目标公司于本公告日期已发行股本总额的2.58%。 本次收购创业慧康控制权，是华检医疗在国家战略指引下，基于对AI医疗产业趋势的深刻洞察，依托 自身独特的"K×A"智能资本模式，对一家拥有深厚积淀与创新活力的行业领军企业进行的战略性投资。 通过此次并购及后续的全面赋能与深度融合，华检医疗将与创业慧康 ...

Group 1 - The core point of the article is that Huajian Medical has agreed to acquire 6.23% of the shares of Chuangye Huikang, marking a strategic investment in the AI healthcare sector [1][2] - The acquisition involves purchasing 96.5251 million A-shares at a price of RMB 5.18 per share, totaling RMB 500 million [1] - Following the acquisition, Huajian Medical is expected to hold approximately 12.64% of the voting rights in Chuangye Huikang, assuming no further changes in the company's capital [1] Group 2 - This acquisition is aligned with national strategic guidance and reflects Huajian Medical's deep insight into the trends of the AI healthcare industry [2] - The investment is based on Huajian Medical's unique "K×A" intelligent capital model, targeting a leading company with strong innovation and industry presence [2] - The collaboration aims to create sustainable and substantial returns for both parties' shareholders and contribute to the advancement of China's healthcare sector [2]

Core Insights - Elon Musk recently shared updates on advancements and long-term plans in artificial intelligence, space technology, and medical technology during an interview with investor Ron Baron, emphasizing a vision for technological innovation and human development [1][2] Group 1: Space Technology - Musk outlined an ambitious plan for space computing, aiming to launch 100 gigawatts of solar-powered AI satellites annually, which he believes will provide the lowest-cost energy solution for large-scale AI applications [1] - The scale of this energy supply is significant, considering the current average electricity load in the U.S. is approximately 460 gigawatts [1] Group 2: AI Development - Musk expressed high regard for TSMC and Samsung in the AI chip manufacturing sector, highlighting ongoing collaborations with both companies and the need for faster chip production and capacity enhancement [1] - He noted that the construction of new wafer fabs takes about five years from initiation to production, which he considers a long time given the rapid pace of technological iteration [1] - Musk claimed that Grok-4-Heavy is currently the smartest AI model, utilizing a "multi-agent parallel collaboration" approach for improved output and continuous enhancement [1] Group 3: Robotics and Healthcare - The Tesla humanoid robot, Optimus, is projected to have significant potential in the medical field, capable of performing complex surgeries with "superhuman precision" [1] - Musk indicated that the scarcity of quality medical resources limits accessibility, and robots could help scale manufacturing to improve healthcare service coverage and eliminate poverty [1] Group 4: Neuralink Progress - Neuralink has implanted brain-machine interface devices in over 10 patients, some of whom were previously unable to move their limbs and are now able to communicate at nearly normal speeds [2] - The project is accelerating, showcasing advancements in brain-computer interface technology [2] Group 5: Personal Wealth Philosophy - Musk clarified that his motivation is not wealth or luxury but rather to maintain sufficient influence to guide his companies forward, focusing on technological innovation and long-term development [2] - He revealed a modest personal lifestyle, owning only a medium-sized home in Austin and a small house at Starbase, without any vacation properties [2] Group 6: Vision for the Future - Musk envisions a future where AI and robotics will fully meet human needs, allowing everyone to benefit from technological advancements [2] - His long-term goals include expanding human consciousness and exploring other star systems, akin to the themes in "Star Trek," while seeking a deeper understanding of the universe [2]